Nkarta Inc

15 articles with Nkarta Inc

• 

  Nkarta Treats First Patient in Phase I Trial for Relapsed/Refractory AMLS and...

  11/13/2020

  Nkarta has treated its first patient in the first-in-human Phase I clinical trial of NKX101, an investigational immunotherapy designed to treat relapsed/refractory acute myeloid leukemia (AML) or higher-risk myelodysplastic syndromes.

• Nkarta Reports Third Quarter 2020 Financial Results

  11/12/2020

  First patientdosed in clinical trial of NKX101, investigational NK cell therapy engineered with NKG2D-targeted CAR, in acute myeloid leukemia and myelodysplastic syndromes

• Nkarta Announces Treatment of First Patient in First-in-Human Clinical Trial of Engineered NKG2D-Based NK Cell Cancer Immunotherapy NKX101First Multi-Center Clinical Trial to Investigate an Engineered NK Cell Targeting NKG2D

  11/12/2020

  Nkarta, Inc., a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, announced that the first patient has been treated in the first-in-human Phase 1 clinical trial of NKX101 for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes.

• Nkarta Announces Presentation of Preclinical Data on NKX019, Engineered NK Cell Therapy Candidate Targeting CD19, at the Annual Meeting of the Society for Immunotherapy of Cancer

  11/9/2020

  Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced a preclinical update on NKX019, its investigational allogeneic cancer immunotherapy that uses donor-derived natural killer (NK) cells engineered with a membrane-bound form of IL15 and a chimeric antigen receptor (CAR) targeting the CD19 antigen.

• Nkarta Announces November & December 2020 Investor Conference Schedule

  11/5/2020

  Nkarta, Inc., a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, announced its participation at these upcoming investor conferences

• Nkarta Announces Leadership Changes

  10/5/2020

  Nkarta, Inc., a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, announced that Nadir Mahmood, Ph.D., Chief Business Officer of Nkarta, is assuming the expanded role of Chief Financial and Business Officer effective immediately.

• Nkarta Announces September 2020 Virtual Investor Conference Schedule

  9/8/2020

  Nkarta, Inc., a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, announced that it will participate at the following virtual investor conference

• Nkarta Reports Second Quarter 2020 Financial Results

  8/20/2020

  Co-Lead programs on track: NKX101 expected to begin Phase 1 dosing in 4Q 2020 and IND for NKX019 expected to be filed in 1Q 2021 Completed construction of cGMP clinical manufacturing facility Completed initial public offering of common stock on July 14, 2020, raising $289.8 million in gross proceeds Cash and cash equivalents of $341.8 million (pro forma) as of June 30, 2020, believed to be sufficient to fund operations into at least the second half of 2023 SOUTH SAN FRANCISCO, Calif

• Nkarta Announces Closing of Upsized Initial Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional SharesUnderwriters’ Full Exercise of Option Brings Gross Proceeds to $289.8 Million

  7/14/2020

  Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the closing of its initial public offering of 16,100,000 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to 2,100,000 additional shares of common stock, at a public offering price of $18.00 per share. The aggregate

• Nkarta Announces Pricing of Initial Public Offering - July 10, 2020

  7/10/2020

  Nkarta, Inc., a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, announced the pricing of its initial public offering of 14,000,000 shares of common stock at a public offering price of $18.00 per share.

• Nkarta Therapeutics Presents Preclinical Findings Supporting Gene Editing of Natural Killer Cells and the Combination of Engineered NK plus T Cells at the American Association for Cancer Research (AACR) Virtual 2020 Annual Meeting II

  6/22/2020

  Gene editing of engineered natural killer cells contributed to enhanced cell persistence and tumor killing Combination of engineered natural killer cells and engineered T cells demonstrated potential to achieve improved tumor control, optimized cell proliferation and moderate levels of cytokine accumulation SOUTH SAN FRANCISCO, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nkarta), a privately-held biopharmaceutical company developing engineered natural killer (NK) cell thera

• 

  How COVID-19 is Affecting Clinical Trials and Drug Supplies from Biotech Bay Companies

  6/5/2020

  Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.

• Abveris Announces Human Antibody Discovery Partnership with Nkarta using the Trianni Mouse® on the Berkeley Lights Beacon®

  5/12/2020

  May 12, 2020 12:13 UTC Abveris Announces Human Antibody Discovery Partnership with Nkarta using the Trianni Mouse ® on the Berkeley Lights Beacon ® CANTON, Mass.--( BUSINESS WIRE )-- Abveris, Inc. (“Abveris”) announced today that it has entered into an antibody discovery partnership with Nkarta, Inc. (“Nkarta”) for the discovery of fully-human monoclonal antibodies to support the advancement of Nkarta’s novel cell-based therapeutics. Under the terms of the agreement, Abveri

• Nkarta Therapeutics Appoints Two New Independent DirectorsIndustry Veterans Laura Shawver, Ph.D. and Leone Patterson Strengthen Board’s Biopharma Leadership

  4/27/2020

  Nkarta, Inc. (Nkarta), a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, announced today the appointments of Laura K. Shawver, Ph.D. and Leone Patterson to its Board of Directors. “With these two appointments, we further enhance Nkarta’s already strong, diverse Board with significant biopharma industry expertise, additional drug development talent and financial a

• Nkarta Therapeutics Presents Preclinical Data for CD19 CAR NK Program

  11/18/2019

  Nkarta Therapeutics announced preclinical data were presented in a poster session at the American Association for Cancer Research, Tumor Immunology and Immunotherapy Meeting 2019 in Boston, Massachusetts.